Drug Trial Radar · NCT03617263
Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)
Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
60
Actual
Start
Feb 12, 2019
Primary completion
Oct 28, 2024
Study completion Oct 28, 2024
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.
Conditions
- Non-alcoholic Fatty Liver Disease in Women With PCOS
Interventions
Saroglitazar Magnesium 4 mg TabletDrug
Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
PlaceboDrug
Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hepatic Fat ContentTime frame: Baseline and Week 24
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
Zydus US005
Chandler, Arizona
Zydus US004
Panorama City, California
Zydus US002
San Francisco, California
Zydus US008
Aurora, Colorado
Zydus US010
Miami, Florida
Zydus US001
Indianapolis, Indiana
Zydus US011
Morehead City, North Carolina
Zydus US003
Marion, Ohio
Zydus US015
Hershey, Pennsylvania
Zydus US014
Philadelphia, Pennsylvania
Zydus US013
Austin, Texas
Zydus US007
San Antonio, Texas
Zydus US009
San Antonio, Texas
Zydus MX003
Mexico City, Mexico
Zydus MX006
Guadalajara, Jalisco, Mexico
Zydus MX001
Monterrey, Nuevo León, Mexico
Zydus MX002
Monterrey, Nuevo León, Mexico
Zydus MX005
Culiacán, Sinaloa, Mexico
Zydus MX004
Mérida, Yucatán, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.